Cetuximab sarotalocan clinical trials
Includes 7 studies of Cetuximab sarotalocan sodium.
How each study uses cetuximab sarotalocan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the cetuximab sarotalocan studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
7 studies that test it; most in 2022 (2)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2020 | 1 |
| 2022 | 2 |
| 2024 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 2
Rakuten Medical, Inc. (5) · Brown University (1) · Roswell Park Cancer Institute (1)
Studies
Open first, then newest update. How each study uses cetuximab sarotalocan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- EGFR Targeted Photoimmunotherapy With ASP-1929 for Locally Advanced Pancreatic CancerNot yet recruitingPhase 1/2Brown UniversityNCT07698613Written as ASP-1929 photoimmunotherapyHow we know
- A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant MetastasesRecruitingPhase 3Rakuten Medical, Inc.NCT06699212Written as ASP-1929 PhotoimmunotherapyHow we know
- Photoimmunotherapy With ASP-1929 and Cemiplimab for the Treatment of Refractory, Inoperable, and Metastatic Stage IIIB-IV Non-small Cell Lung CancerWithdrawnPhase 2Roswell Park Cancer InstituteNCT06943664Written as Cetuximab Sarotalocan SodiumHow we know
- An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid TumorsActive, not recruitingPhase 1/2Rakuten Medical, Inc.NCT04305795Written as ASP-1929 PITHow we know
- ASP-1929 Photoimmunotherapy (PIT) Study in Recurrent Head/Neck Cancer for Patients Who Have Failed at Least Two Lines of TherapyActive, not recruitingPhase 3Rakuten Medical, Inc.NCT03769506Written as ASP-1929 PhotoimmunotherapyHow we know
- ASP-1929 Photoimmunotherapy Combined With Pembrolizumab in Patients With Recurrent Head and Neck Cancer, With or Without MetastasesTerminatedPhase 2Rakuten Medical, Inc.NCT05265013Written as ASP-1929 PhotoimmunotherapyHow we know
- ASP-1929 Photoimmunotherapy (PIT) Study in Patients With Recurrent Head/Neck CancerActive, not recruitingPhase 2Rakuten Medical, Inc.NCT05182866Written as ASP-1929 PhotoimmunotherapyHow we know
Codes
What other systems call cetuximab sarotalocan · ClinicalTrials.gg INT018918
- UNII (FDA) U7S8ZU4L3MCETUXIMAB SAROTALOCANOne source FDA
- NCI Thesaurus C190488Cetuximab SarotalocanOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | U7S8ZU4L3M | CETUXIMAB SAROTALOCAN | One source FDA |
| NCI Thesaurus | C190488 | Cetuximab Sarotalocan | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.